AP517A - Combination of atovaquone and proguanil and its use in treatment of protozoal infections. - Google Patents

Combination of atovaquone and proguanil and its use in treatment of protozoal infections. Download PDF

Info

Publication number
AP517A
AP517A APAP/P/1993/000592A AP9300592A AP517A AP 517 A AP517 A AP 517A AP 9300592 A AP9300592 A AP 9300592A AP 517 A AP517 A AP 517A
Authority
AP
ARIPO
Prior art keywords
proguanil
atovaquone
hydroxy
combination
naphthoquinone
Prior art date
Application number
APAP/P/1993/000592A
Other languages
English (en)
Other versions
AP9300592A0 (en
Inventor
Winston Edward Gutteridge
David Brian Ashton Hutchinson
Victoria Susan Latter
Mary Pudney
Original Assignee
The Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10725687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP517(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Wellcome Foundation Ltd filed Critical The Wellcome Foundation Ltd
Publication of AP9300592A0 publication Critical patent/AP9300592A0/xx
Application granted granted Critical
Publication of AP517A publication Critical patent/AP517A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
APAP/P/1993/000592A 1992-11-26 1993-11-25 Combination of atovaquone and proguanil and its use in treatment of protozoal infections. AP517A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929224739A GB9224739D0 (en) 1992-11-26 1992-11-26 Medicaments

Publications (2)

Publication Number Publication Date
AP9300592A0 AP9300592A0 (en) 1994-01-31
AP517A true AP517A (en) 1996-08-23

Family

ID=10725687

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1993/000592A AP517A (en) 1992-11-26 1993-11-25 Combination of atovaquone and proguanil and its use in treatment of protozoal infections.

Country Status (38)

Country Link
US (3) US5998449A (sl)
EP (1) EP0670719B1 (sl)
JP (1) JP3768231B2 (sl)
KR (1) KR100294802B1 (sl)
CN (1) CN1087935C (sl)
AP (1) AP517A (sl)
AT (1) ATE191340T1 (sl)
AU (1) AU685408B2 (sl)
BG (1) BG62595B1 (sl)
CA (1) CA2150234E (sl)
CY (1) CY2193B1 (sl)
CZ (2) CZ289171B6 (sl)
DE (1) DE69328307T2 (sl)
DK (1) DK0670719T3 (sl)
ES (1) ES2145114T3 (sl)
GB (1) GB9224739D0 (sl)
GR (1) GR3033745T3 (sl)
HK (1) HK1004468A1 (sl)
HU (1) HU225918B1 (sl)
IL (1) IL107755A (sl)
MX (1) MX9307402A (sl)
MY (1) MY114241A (sl)
NO (1) NO313225B1 (sl)
NZ (1) NZ257901A (sl)
OA (1) OA10352A (sl)
PE (1) PE55694A1 (sl)
PL (1) PL174323B1 (sl)
PT (1) PT670719E (sl)
RO (1) RO119280B1 (sl)
RU (1) RU2108092C1 (sl)
SA (1) SA93140434B1 (sl)
SG (1) SG45387A1 (sl)
SI (1) SI9300614A (sl)
SK (1) SK281559B6 (sl)
TW (1) TW253835B (sl)
UA (1) UA45948C2 (sl)
WO (1) WO1994012164A1 (sl)
ZA (1) ZA938832B (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224739D0 (en) * 1992-11-26 1993-01-13 Wellcome Found Medicaments
GB9424013D0 (en) * 1994-11-29 1995-01-18 Wellcome Found Medicaments
DE19737463A1 (de) * 1997-08-28 1999-03-04 Hoechst Marion Roussel De Gmbh Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden
GB9822681D0 (en) * 1998-10-16 1998-12-09 Vitabiotics Ltd Method of treatment
ES2199817T3 (es) * 1999-04-09 2004-03-01 Glaxo Group Limited Preparacion combinada para tratar la malaria.
US7104076B2 (en) * 2004-06-24 2006-09-12 Carrier Corporation Lubricant return schemes for use in refrigerant cycle
ITMI20070941A1 (it) * 2007-05-09 2008-11-10 Chimico Internazi0Nale S P A L Procedimento per la preparazione di naftochinoni trans2,3-disostituiti
WO2011021230A2 (en) * 2009-08-20 2011-02-24 Ipca Laboratories Limited Novel complex for treatment and/or prophylaxis of parasitic infections
US20180055835A1 (en) 2016-08-25 2018-03-01 Immune Therapeutics Inc. Method for Treating And Preventing Protozoal Infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0123238A2 (en) * 1983-04-14 1984-10-31 The Wellcome Foundation Limited Naphthoquinone derivatives

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2533648A (en) * 1949-03-05 1950-12-12 Joseph H Warburg Circular saw making
NL6411993A (sl) * 1963-10-18 1965-04-20
US3347830A (en) * 1964-07-30 1967-10-17 Grace W R & Co Process of polymerizing formaldehyde
GB1141735A (en) * 1966-11-23 1969-01-29 Pfizer & Co C Pharmaceutical anti-tumor composition
NL6817526A (sl) * 1968-01-24 1969-07-28
US3655699A (en) * 1970-03-02 1972-04-11 Pfizer Analogues of lapachol as antitumor agents
DE2601458A1 (de) * 1975-01-20 1976-07-22 Ciba Geigy Ag Loesliche, von phenylindandiaminen abgeleitete polyamide
JPS5492945A (en) * 1977-11-22 1979-07-23 Wellcome Found Naphthoquinone derivative
US4485116A (en) * 1981-10-16 1984-11-27 Hudson Alan T Antiprotozoal compounds
US4485117A (en) * 1981-10-16 1984-11-27 Hudson Alan T Antiprotozoal compounds
GB8310140D0 (en) * 1983-04-14 1983-05-18 Wellcome Found Antiprotozoal agents
US5053432A (en) * 1983-04-14 1991-10-01 Burroughs Wellcome Co. Naphthoquinone derivatives
JPS59196467A (ja) * 1983-04-23 1984-11-07 Nissan Motor Co Ltd 車輪速及びまたは車輪加減速度検出方法
US5225184A (en) * 1988-08-16 1993-07-06 Burroughs Wellcome Co. Medicaments
GB8819477D0 (en) * 1988-08-16 1988-09-21 Wellcome Found Medicaments
ATE178311T1 (de) * 1988-08-16 1999-04-15 Wellcome Found Neue naphthochinone und ihre anwendung als arzneimittel
US5206268A (en) * 1988-08-16 1993-04-27 Burroughs Wellcome Co. Medicaments
GB8921516D0 (en) * 1989-09-22 1989-11-08 Wellcome Found Medicaments
GB8923254D0 (en) * 1989-10-16 1989-12-06 Wellcome Found Medicaments
US5014737A (en) * 1989-11-13 1991-05-14 Allan Berman Quartz integrated trough/sump recirculating filtered high-purity chemical bath
GB9121316D0 (en) * 1991-10-09 1991-11-20 Wellcome Found Heterocyclic compounds
GB9224739D0 (en) * 1992-11-26 1993-01-13 Wellcome Found Medicaments
GB9226905D0 (en) * 1992-12-24 1993-02-17 Wellcome Found Pharmaceutical preparation
ATE143601T1 (de) * 1993-05-05 1996-10-15 Palo Alto Medical Found Verwendung von rifamycinderivaten zur herstellung eines arzneimittels zur behandlung der toxoplasmose
US5529994A (en) * 1993-05-05 1996-06-25 Palo Alto Medical Foundation Treatment for toxoplasmosis
US5733932A (en) * 1995-01-06 1998-03-31 The Picower Institute For Medical Research Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions
US5827543A (en) * 1995-12-07 1998-10-27 The Procter & Gamble Company Methods and compositions for the prevention and treatment of urogenital disorders
US5744168A (en) * 1995-12-07 1998-04-28 The Procter & Gamble Company Methods and compositions for the prevention and treatment of gastrointestinal disorders
US5747476A (en) * 1996-07-17 1998-05-05 Mortar & Pestle Veterinary Pharmacy, Inc. Treatment of equine protozoal myeloencephalitis
ZA983331B (en) * 1997-05-01 1998-10-27 Allegheny University Of The He Method for treating protozoal infections
AUPO821097A0 (en) * 1997-07-25 1997-08-14 Cultor Ltd. A prophylactic
DE19737463A1 (de) * 1997-08-28 1999-03-04 Hoechst Marion Roussel De Gmbh Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden
ES2199817T3 (es) * 1999-04-09 2004-03-01 Glaxo Group Limited Preparacion combinada para tratar la malaria.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0123238A2 (en) * 1983-04-14 1984-10-31 The Wellcome Foundation Limited Naphthoquinone derivatives

Also Published As

Publication number Publication date
US5998449A (en) 1999-12-07
CN1087935C (zh) 2002-07-24
AP9300592A0 (en) 1994-01-31
ATE191340T1 (de) 2000-04-15
SK281559B6 (sk) 2001-05-10
CA2150234E (en) 2005-03-22
GB9224739D0 (en) 1993-01-13
HU9501537D0 (en) 1995-07-28
BG62595B1 (bg) 2000-03-31
SA93140434B1 (ar) 2004-09-01
PL174323B1 (pl) 1998-07-31
CZ289692B6 (cs) 2002-03-13
HU225918B1 (en) 2007-12-28
DK0670719T3 (da) 2000-07-31
CZ289171B6 (cs) 2001-11-14
TW253835B (sl) 1995-08-11
EP0670719A1 (en) 1995-09-13
HUT71346A (en) 1995-11-28
NO951995D0 (no) 1995-05-19
AU685408B2 (en) 1998-01-22
DE69328307T2 (de) 2000-10-26
CN1091632A (zh) 1994-09-07
KR100294802B1 (ko) 2001-09-17
RU2108092C1 (ru) 1998-04-10
CA2150234A1 (en) 1994-06-09
PE55694A1 (es) 1995-01-25
PT670719E (pt) 2000-09-29
GR3033745T3 (en) 2000-10-31
US6291488B1 (en) 2001-09-18
NO313225B1 (no) 2002-09-02
PL309222A1 (en) 1995-10-02
NZ257901A (en) 1997-01-29
WO1994012164A1 (en) 1994-06-09
BG99656A (bg) 1996-04-30
SK57095A3 (en) 1996-05-08
IL107755A (en) 2000-10-31
MY114241A (en) 2002-09-30
DE69328307D1 (de) 2000-05-11
ZA938832B (en) 1995-05-25
IL107755A0 (en) 1994-02-27
NO951995L (no) 1995-07-03
SI9300614A (en) 1994-06-30
US6166046A (en) 2000-12-26
UA45948C2 (uk) 2002-05-15
SG45387A1 (en) 1998-01-16
RO119280B1 (ro) 2004-07-30
HK1004468A1 (en) 1998-11-27
AU5532294A (en) 1994-06-22
JPH08503938A (ja) 1996-04-30
CY2193B1 (en) 2002-11-08
ES2145114T3 (es) 2000-07-01
MX9307402A (es) 1994-07-29
CZ119295A3 (en) 1995-11-15
EP0670719B1 (en) 2000-04-05
OA10352A (en) 2001-10-22
CA2150234C (en) 2001-01-16
JP3768231B2 (ja) 2006-04-19

Similar Documents

Publication Publication Date Title
AP517A (en) Combination of atovaquone and proguanil and its use in treatment of protozoal infections.
EP0572615B1 (en) Medicament for the Treatment of Protozoal Infections caused by Babesia
EP0445141B1 (en) Medicaments for the treatment of toxoplasmosis
EP0653936B1 (en) Use of 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone for the treatment of cancer
US5856362A (en) Medicaments for the treatment of toxoplasmosis
EP0496729B1 (en) Medicament for the treatment of cryptosporidiosis
EP0567162A1 (en) Medicaments for the treatment of toxoplasmosis
WO1996016652A2 (en) Use of rifabutin and a combination of rifabutin and atovaquone in the treatment of pneumocystis carinii infections